Company intelligence / Profile preview

AUXILIO

Chesterbrook, Pennsylvania, United States

Ownership: Private
Employees: ~600
Development stage: Other

Overview

Auxilium Pharmaceuticals was a specialty biopharmaceutical company focused on developing and commercializing innovative products for urology, sexual health, and orthopedic conditions. The company's flagship product, Xiaflex (collagenase clostridium histolyticum), became a standard of care for Dupuytren's contracture and Peyronie's disease. Auxilium also marketed Testim, a testosterone replacement therapy, and Stendra for erectile dysfunction. In 2015, the company was acquired by Endo International, which integrated Auxilium's portfolio into its specialty branded pharmaceutical business.

Therapeutic areas: EndocrinologyMen's HealthRheumatologyDermatology
Modalities: Small moleculeBiologicProteinRecombinant protein
Industry: Biotech

Partnerships

Asahi Kasei PharmaSwedish Orphan BiovitrumVivus

Beyond the preview

Go deeper on AUXILIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUXILIO.

Explore the full profile